Evidence map›Paper›PMID 34579975›Full record

ArticleVaccine2021

Vaccination information, motivations, and barriers in the context of meningococcal serogroup A conjugate vaccine introduction: A qualitative assessment among caregivers in Burkina Faso, 2018.

Brooke Noel Aksnes, Jenny A Walldorf, Sylvain F Nkwenkeu, Robert L Zoma, Imran Mirza, Felix Tarbangdo, Soukeynatou Fall, Sansan Hien, Cesaire Ky, Ludovic Kambou and 9 more

Open access · hybridAbstract read
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 5 institutions in 2 countries.

Brooke Noel AksnesCenters for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Jenny A WalldorfCenters for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Sylvain F NkwenkeuUNICEF Ouagadougou, Burkina Faso.
Robert L ZomaInstitut National de Statistique et Démographie, Ouagadougou, Burkina Faso.
Imran MirzaUNICEF, New York, NY 10017, USA.
Felix TarbangdoDavycas International, Ouagadougou, Burkina Faso.
Soukeynatou FallUNICEF Ouagadougou, Burkina Faso.
Sansan HienUNICEF Ouagadougou, Burkina Faso.
Cesaire KyMinistère de la Santé, Ouagadougou, Burkina Faso.
Ludovic KambouMinistère de la Santé, Ouagadougou, Burkina Faso.
Alpha Oumar DialloCenters for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Flavien H AkéDavycas International, Ouagadougou, Burkina Faso.
Cynthia HatcherCenters for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Jaymin C PatelCenters for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Ryan T NovakCenters for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Terri B HydeCenters for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Isaïe MedahMinistère de la Santé, Ouagadougou, Burkina Faso.
Heidi M SoetersCenters for Disease Control and Prevention, Atlanta, GA, 30329, USA. Electronic address: HMSoeters@cdc.gov.
Mohamed F JallohCenters for Disease Control and Prevention, Atlanta, GA, 30329, USA.
Centers for Disease Control and Prevention · USMinistère De La Santé · BFUniversité Joseph Ki-Zerbo · BFInternational Institute for Water and Environmental Engineering · BFUnited Nations Children's Fund · US

Funding

Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundIn March 2017, Burkina Faso introduced meningococcal serogroup A conjugate vaccine (MACV) into the Expanded Programme on Immunization. MACV is administered to children aged 15-18 months, concomitantly with the second dose of measles-containing vaccine (MCV2). One year after MACV introduction, we assessed the sources and content of immunization information available to caregivers and explored motivations and barriers that influence their decision to seek MACV for their children.

methodsTwenty-four focus group discussions (FGDs) were conducted with caregivers of children eligible for MACV and MCV2. Data collection occurred in February-March 2018 in four purposively selected districts, each from a separate geographic region; within each district, caregivers were stratified into groups based on whether their children were unvaccinated or vaccinated with MACV. FGDs were recorded and transcribed. Transcripts were coded and analyzed using qualitative content analysis.

resultsWe identified many different sources and content of information about MACV and MCV2 available to caregivers. Healthcare workers were most commonly cited as the main sources of information; caregivers also received information from other caregivers in the community. Caregivers' motivations to seek MACV for their children were driven by personal awareness, engagements with trusted messengers, and perceived protective benefits of MACV against meningitis. Barriers to MACV and MCV2 uptake were linked to the unavailability of vaccines, immunization personnel not providing doses, knowledge gaps about the 15-18 month visit, practical constraints, past negative experiences, sociocultural influences, and misinformation, including misunderstanding about the need for MCV2.

conclusionsMACV and MCV2 uptake may be enhanced by addressing vaccination barriers and effectively communicating vaccination information and benefits through trusted messengers such as healthcare workers and other caregivers in the community. Educating healthcare workers to avoid withholding vaccines, likely due to fear of wastage, may help reduce missed opportunities for vaccination.

Indexed as

Meningitis, MeningococcalMeningococcal VaccinesBurkina FasoCaregiversChildHumansInfantMotivationSerogroupVaccinationVaccines, ConjugateMeningococcal VaccinesVaccines, ConjugateBurkina FasoImmunization scheduleMeasles vaccineMeningococcal serogroup A conjugate vaccineVaccination challengesVaccine introduction

Identifiers

PMID34579975
PMCPMC8519392
OpenAlexW3202135617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.